Key Points
- Francisco Partners sold 447,259 GoodRx shares at an average price of $3.52, generating approximately $1.57 million. The sale reduced its GoodRx ownership by 32.87% to 913,592 shares.
- GoodRx reported quarterly EPS of $0.08, matching estimates, while revenue of $200.4 million exceeded expectations but declined 1.3% year over year. The stock opened at $3.45, with a 12-month range of $1.77 to $5.81.
- Analyst sentiment remains mixed: GoodRx has an overall “Hold” rating and an average price target of $4.23, although TD Cowen and Citigroup raised their targets to $5 and maintained “Buy” ratings.
GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) major shareholder Francisco Partners Iv, L.P. sold 274,717 shares of the firm's stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $3.50, for a total value of $961,509.50. Following the completion of the sale, the insider directly owned 777,213 shares of the company's stock, valued at approximately $2,720,245.50. The trade was a 26.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
Francisco Partners Iv, L.P. also recently made the following trade(s):
- On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The stock was sold at an average price of $3.52, for a total value of $1,574,351.68.
- On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The stock was sold at an average price of $3.53, for a total value of $1,666,071.75.
GoodRx Stock Down 3.1%
GDRX opened at $3.45 on Friday. GoodRx Holdings, Inc. has a 1-year low of $1.77 and a 1-year high of $5.81. The stock's fifty day simple moving average is $3.13 and its 200 day simple moving average is $2.63. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.74. The stock has a market cap of $1.18 billion, a PE ratio of 86.27, a price-to-earnings-growth ratio of 1.77 and a beta of 1.60.
GoodRx (NASDAQ:GDRX - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, hitting analysts' consensus estimates of $0.08. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The firm had revenue of $200.41 million during the quarter, compared to analysts' expectations of $193.23 million. During the same period in the previous year, the business posted $0.09 earnings per share. The company's revenue for the quarter was down 1.3% compared to the same quarter last year. As a group, research analysts expect that GoodRx Holdings, Inc. will post 0.16 earnings per share for the current year.
Hedge Funds Weigh In On GoodRx
Hedge funds have recently modified their holdings of the business. Prescott Group Capital Management L.L.C. acquired a new stake in GoodRx during the fourth quarter worth approximately $4,812,000. Technology Crossover Management X Ltd. bought a new position in GoodRx in the 2nd quarter valued at about $4,762,000. Northwestern Mutual Wealth Management Co. boosted its position in shares of GoodRx by 10,242.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,502,666 shares of the company's stock valued at $4,072,000 after buying an additional 1,488,137 shares during the last quarter. AQR Capital Management LLC raised its position in GoodRx by 188.0% in the 4th quarter. AQR Capital Management LLC now owns 1,158,546 shares of the company's stock valued at $3,140,000 after buying an additional 756,209 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in GoodRx by 7.3% during the 3rd quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company's stock valued at $38,947,000 after acquiring an additional 624,182 shares in the last quarter. Institutional investors and hedge funds own 63.77% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts have weighed in on the stock. Wells Fargo & Company increased their price target on shares of GoodRx from $3.50 to $5.00 and gave the company an "overweight" rating in a report on Friday, August 7th. TD Cowen upped their target price on GoodRx from $4.00 to $5.00 and gave the company a "buy" rating in a research report on Tuesday, August 11th. Citigroup increased their target price on GoodRx from $4.00 to $5.00 and gave the stock a "buy" rating in a research note on Tuesday, August 11th. Leerink Partners set a $5.00 price target on GoodRx in a report on Thursday, August 6th. Finally, The Goldman Sachs Group reissued a "neutral" rating and issued a $4.00 target price on shares of GoodRx in a research report on Friday, August 7th. Four analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $4.23.
View Our Latest Stock Analysis on GoodRx
GoodRx Company Profile
(
Get Free Report)
GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.
In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
